Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs

@inproceedings{Colhoun2012HospitalisedHF,
  title={Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs},
  author={Helen M. Colhoun and Shona J. Livingstone and Helen C. Looker and Andrew D. Morris and Sarah H Wild and R. S. Lindsay and Craig Reed and Peter T. Donnan and Bruce Guthrie and Graham Peter Leese and J Mcknight and Donald W M Pearson and Ewan Robert Pearson and John R Petrie and Sam Philip and Naveed Sattar and Frank M. Sullivan and Paul McKeigue},
  booktitle={Diabetologia},
  year={2012}
}
Current drug labels for thiazolidinediones (TZDs) warn of increased fractures, predominantly for distal fractures in women. We examined whether exposure to TZDs affects hip fracture in women and men and compared the risk to that found with other drugs used in diabetes. Using a nationwide database of prescriptions, hospital admissions and deaths in those with type 2 diabetes in Scotland we calculated TZD exposure among 206,672 individuals. Discrete-time failure analysis was used to model the… CONTINUE READING